FINHUB Insights

DXCM · Q2 FY26 · Apr 1 – Jun 30, 2026

Dexcom Q2 FY26: where the revenue came from and where it went

Dexcom Q2 FY26: revenue $1.3B (+13% year over year). Net profit $0.25B. Largest cohort United States $0.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Apr 30, 2026 10-Q
Sankey diagram of Dexcom's income statement for Q2 FY26: revenue of $1.31 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.31B +13% year over year
Gross profit$0.83B 63% margin
Operating profit$0.32B 24% margin
Net profit$0.25B 19% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 1.31 100% +13%
United States 0.83 64%
International 0.36 28%
Other 0.12 9%
Cost of revenue−0.4837%
Gross profit0.8363% margin+4pp
Research & development−0.1512%−1pp
SG&A−0.3627%−1pp
Operating profit0.3224% margin+6pp
Tax−0.07
Net profit0.2519%+3pp
Filing on EDGAR More quarters of DXCM

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters